

Palbociclib: an evidence-based review of its potential in

Breast Cancer: Targets and Therapy

6, 123

DOI: [10.2147/bctt.s46725](https://doi.org/10.2147/bctt.s46725)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer: Basic and Clinical Research, 2015, 9s2, BCBCR.S29420.	0.6	172
2	Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S31586.	0.6	15
3	Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine's Tool Box. Molecules, 2015, 20, 16852-16891.	1.7	471
4	CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?. Frontiers in Oncology, 2015, 5, 259.	1.3	28
5	Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth. Scientific Reports, 2015, 5, 10433.	1.6	43
6	Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nature Medicine, 2015, 21, 1424-1435.	15.2	1,547
7	Mechanisms of hormonal therapy resistance in breast cancer. International Journal of Clinical Oncology, 2015, 20, 262-267.	1.0	14
8	Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research, 2015, 21, 1514-1524.	3.2	205
9	Targeting Breast Cancer with CDK Inhibitors. Current Oncology Reports, 2015, 17, 443.	1.8	67
10	Brk/Protein Tyrosine Kinase 6 Phosphorylates p27 ^{KIP1} , Regulating the Activity of Cyclin D-Cyclin-Dependent Kinase 4. Molecular and Cellular Biology, 2015, 35, 1506-1522.	1.1	41
11	Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. International Journal of Molecular Sciences, 2015, 16, 9314-9340.	1.8	58
12	Palbociclib: First Global Approval. Drugs, 2015, 75, 543-551.	4.9	109
13	Development of cell-cycle checkpoint therapy for solid tumors. Japanese Journal of Clinical Oncology, 2015, 45, hvv131.	0.6	31
14	Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmacological Inhibitors of the CDK4/6 Cell-Cycle Pathway. Cancer Research, 2015, 75, 3823-3831.	0.4	73
15	Durability of Kinase-Directed Therapies-A Network Perspective on Response and Resistance. Molecular Cancer Therapeutics, 2015, 14, 1975-1984.	1.9	22
16	The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. Oncotarget, 2016, 7, 40846-40859.	0.8	61
17	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. Journal of Cancer, 2016, 7, 947-956.	1.2	9
18	Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer: Targets and Therapy, 2016, 8, 83.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Origin of aromatase inhibitory activity via proteochemometric modeling. PeerJ, 2016, 4, e1979.	0.9	16
20	Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. ESMO Open, 2016, 1, e000093.	2.0	27
21	Palbociclib: A breakthrough in breast carcinoma in women. Medical Journal Armed Forces India, 2016, 72, S37-S42.	0.3	7
22	<i>pRB1</i> : a prototype tumor suppressor and an enigma. Genes and Development, 2016, 30, 1492-1502.	2.7	360
23	Targeting the androgen receptor in triple-negative breast cancer. Current Problems in Cancer, 2016, 40, 141-150.	1.0	70
24	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. Npj Breast Cancer, 2017, 3, 9.	2.3	47
25	Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. British Journal of Cancer, 2017, 116, 10-20.	2.9	13
26	Interchangeable Roles for E2F Transcriptional Repression by the Retinoblastoma Protein and p27 ^{KIP1} Cyclin-Dependent Kinase Regulation in Cell Cycle Control and Tumor Suppression. Molecular and Cellular Biology, 2017, 37, .	1.1	19
27	HR+, HER2 ⁺ Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Current Cancer Drug Targets, 2017, 17, 637-649.	0.8	65
28	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes, 2017, 8, 217.	1.0	24
29	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. Molecular Cancer Therapeutics, 2018, 17, 1114-1122.	1.9	47
30	Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. Molecular Cancer Research, 2018, 16, 361-377.	1.5	48
31	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clinical Cancer Research, 2018, 24, 521-531.	3.2	64
32	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
33	One-Pot Synthesis of 6-Aminopyrido[2,3-d]pyrimidines. European Journal of Organic Chemistry, 2018, 2018, 6519-6523.	1.2	6
34	Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition. International Journal of Breast Cancer, 2018, 2018, 1-11.	0.6	19
35	CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. Journal of Neuro-Oncology, 2019, 144, 583-589.	1.4	48
36	Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials. Cancer Medicine, 2019, 8, 1389-1400.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. <i>Cancer Science</i> , 2019, 110, 1420-1430.	1.7	48
38	Pyrido[2,3-d]pyrimidin-7(8H)-ones: Synthesis and Biomedical Applications. <i>Molecules</i> , 2019, 24, 4161.	1.7	25
39	Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells. <i>Metabolites</i> , 2019, 9, 7.	1.3	10
40	Cyclin-Dependent Kinase and Antioxidant Gene Expression in Cancers with Poor Therapeutic Response. <i>Pharmaceuticals</i> , 2020, 13, 26.	1.7	1
41	Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. <i>Journal of Translational Medicine</i> , 2021, 19, 7.	1.8	0
42	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	12
43	Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. <i>Journal of Controlled Release</i> , 2020, 323, 624-634.	4.8	64
44	Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 81-95.	8.2	62
45	A non-canonical Hedgehog pathway initiates ciliogenesis and autophagy. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	31
46	Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. <i>Oncotarget</i> , 2017, 8, 38309-38325.	0.8	25
47	Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. <i>Oncotarget</i> , 2015, 6, 34629-34648.	0.8	26
48	Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. <i>Oncotarget</i> , 2015, 6, 41794-41808.	0.8	69
49	Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors. <i>International Journal of Cancer and Clinical Research</i> , 2015, 2, .	0.1	22
50	Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 550-561.	0.2	1
52	Pyrido[2,3-d]pyrimidin-7-ones: synthesis and biological properties. <i>Journal of Organic and Pharmaceutical Chemistry</i> , 2019, 17, 5-17.	0.0	0
55	Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. <i>American Journal of Cancer Research</i> , 2018, 8, 183-191.	1.4	2
56	Senescence-Associated Molecules and Tumor-Immune-Interactions as Prognostic Biomarkers in Colorectal Cancer. <i>Frontiers in Medicine</i> , 2022, 9, 865230.	1.2	9
57	Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases. <i>Meditsinskiy Sovet</i> , 2022, , 42-51.	0.1	0

#	ARTICLE	IF	CITATIONS
58	Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies. <i>Biomedicines</i> , 2023, 11, 85.	1.4	5
59	Insights into the Peritumoural Brain Zone of Glioblastoma: CDK4 and EXT2 May Be Potential Drivers of Malignancy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2835.	1.8	5
60	Medicinal chemistry perspective of pyrido[2,3- <i>d</i>]pyrimidines as anticancer agents. <i>RSC Advances</i> , 2023, 13, 6872-6908.	1.7	9
61	A mass balance study of [¹⁴ C]SHR6390 (dalciclib), a selective and potent CDK4/6 inhibitor in humans. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
62	Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases. <i>Pharmaceuticals</i> , 2023, 16, 519.	1.7	0